1. Home
  2. MYND vs LEXX Comparison

MYND vs LEXX Comparison

Compare MYND & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mynd.ai Inc.

MYND

Mynd.ai Inc.

N/A

Current Price

$0.35

Market Cap

17.9M

Sector

Real Estate

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

N/A

Current Price

$3.19

Market Cap

8.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MYND
LEXX
Founded
1998
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
8.7M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
MYND
LEXX
Price
$0.35
$3.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.9K
★ 82.6K
Earning Date
08-27-2026
07-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $705,923.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$6,915.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 52.05
52 Week Low
$0.28
$0.35
52 Week High
$0.95
$14.37

Technical Indicators

Market Signals
Indicator
MYND
LEXX
Relative Strength Index (RSI) 53.54 35.47
Support Level $0.30 $0.57
Resistance Level $0.44 $12.89
Average True Range (ATR) 0.05 0.51
MACD 0.00 -0.12
Stochastic Oscillator 53.21 25.92

Price Performance

Historical Comparison
MYND
LEXX

About MYND Mynd.ai Inc.

Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: